A Review of the Partner Trials

Ryan Markham; Rahul Sharma

doi:10.1016/j.iccl.2020.07.002

A Review of the Partner Trials

Interv Cardiol Clin. 2020 Oct;9(4):461-467. doi: 10.1016/j.iccl.2020.07.002.

Authors

Ryan Markham¹, Rahul Sharma²

Affiliations

¹ Stanford Hospital, Palo Alto, CA, USA; Department of Cardiovascular Medicine, Stanford Hospital, 300 Pasteur Drive, Room H2103, Stanford, CA 94305, USA.
² Stanford Hospital, Palo Alto, CA, USA; Department of Cardiovascular Medicine, Stanford Hospital, 300 Pasteur Drive, Room H2103, Stanford, CA 94305, USA. Electronic address: rpsharma@stanford.edu.

PMID: 32921370
DOI: 10.1016/j.iccl.2020.07.002

Abstract

Aortic stenosis (AS) of moderate or greater severity has an estimated prevalence of 5% in people older than 65 years. Survival is poor after onset of symptoms, and surgical aortic valve replacement was the gold-standard treatment for decades. However, more than one-third of patients with symptomatic AS were untreated due to high surgical risk, exposing a clinical need for a less invasive therapy for aortic valve stenosis. The PARTNER trials were pivotal in presenting robust evidence for the safety, feasibility, and efficacy of transcatheter aortic valve replacement in the management of AS and paved the way for clinical use worldwide.

Keywords: Aortic stenosis; Aortic valve replacement; Clinical trial; PARTNER; Sapien heart valve; TAVR.

Publication types

Review

MeSH terms

Aortic Valve / surgery*
Aortic Valve Stenosis / surgery*
Clinical Trials as Topic*
Heart Valve Prosthesis*
Humans
Transcatheter Aortic Valve Replacement / methods*